| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1036198181 |
| P356 | DOI | 10.1007/S11912-012-0227-Y |
| P698 | PubMed publication ID | 22350330 |
| P50 | author | Nicolas Chapuis | Q51322110 |
| Jerome Tamburini | Q48282150 | ||
| Didier Bouscary | Q48282168 | ||
| P2093 | author name string | Catherine Lacombe | |
| Lise Willems | |||
| Patrick Mayeux | |||
| P2860 | cites work | Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2 | Q21145847 |
| Activation of mTORC2 by association with the ribosome | Q24294876 | ||
| Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex | Q24295120 | ||
| mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1) | Q24324148 | ||
| 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase | Q24336639 | ||
| PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer | Q24338724 | ||
| Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus | Q24600932 | ||
| Akt and autophagy cooperate to promote survival of drug-resistant glioma | Q24629677 | ||
| mTOR: from growth signal integration to cancer, diabetes and ageing | Q24633662 | ||
| mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice | Q24658113 | ||
| NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. | Q27851451 | ||
| PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth | Q28243336 | ||
| SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity | Q28262782 | ||
| Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1 | Q28276788 | ||
| Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB | Q28306356 | ||
| The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. | Q50506558 | ||
| Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. | Q53526869 | ||
| PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis | Q39653523 | ||
| Nuclear Phospho-Akt Increase Predicts Synergy of PI3K Inhibition and Doxorubicin in Breast and Ovarian Cancer | Q39657784 | ||
| Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. | Q39832054 | ||
| A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity | Q40028705 | ||
| A critical role for Lyn in acute myeloid leukemia. | Q40040911 | ||
| Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. | Q40118489 | ||
| Syk-dependent mTOR activation in follicular lymphoma cells. | Q40243215 | ||
| Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. | Q40490617 | ||
| mTORC2 protein complex-mediated Akt (Protein Kinase B) Serine 473 Phosphorylation is not required for Akt1 activity in human platelets [corrected]. | Q42813304 | ||
| AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity | Q43211411 | ||
| Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. | Q46003222 | ||
| PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. | Q46544691 | ||
| Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN | Q28513537 | ||
| mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt | Q29547767 | ||
| Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity | Q29614241 | ||
| An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1 | Q29614563 | ||
| PI3K pathway alterations in cancer: variations on a theme | Q29615530 | ||
| Targeting the phosphoinositide 3-kinase pathway in cancer | Q29615809 | ||
| Targeting PI3K signalling in cancer: opportunities, challenges and limitations | Q29617685 | ||
| Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer | Q29618030 | ||
| Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity | Q29618117 | ||
| Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor | Q33597663 | ||
| The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. | Q33928657 | ||
| The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo | Q33939369 | ||
| Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo. | Q34147950 | ||
| Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy | Q34306865 | ||
| AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity | Q34511038 | ||
| Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors | Q35091507 | ||
| Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling | Q35370616 | ||
| Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy | Q35556966 | ||
| Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62/sequestosome 1 | Q35562833 | ||
| mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling | Q35581650 | ||
| mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells | Q35631301 | ||
| Defining the role of TORC1/2 in multiple myeloma | Q35631315 | ||
| Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy | Q35640228 | ||
| Predicted mechanisms of resistance to mTOR inhibitors | Q36585744 | ||
| Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR) | Q37257487 | ||
| Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia | Q37331742 | ||
| mTOR signaling and drug development in cancer | Q37710367 | ||
| Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies | Q37779489 | ||
| The biological and therapeutic relevance of mRNA translation in cancer | Q37848652 | ||
| New phosphatidylinositol 3-kinase inhibitors for cancer | Q37851994 | ||
| Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. | Q37865381 | ||
| Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo | Q39491650 | ||
| Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin | Q39524587 | ||
| Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates | Q39538508 | ||
| The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells. | Q39546457 | ||
| Formation of the eIF4F translation-initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptors. | Q39557642 | ||
| Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. | Q39590044 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 129-138 | |
| P577 | publication date | 2012-04-01 | |
| P1433 | published in | Current Oncology Reports | Q2264969 |
| P1476 | title | PI3K and mTOR signaling pathways in cancer: new data on targeted therapies | |
| P478 | volume | 14 |
| Q36010786 | A Set of miRNAs, Their Gene and Protein Targets and Stromal Genes Distinguish Early from Late Onset ER Positive Breast Cancer |
| Q35975058 | AZD2014 Radiosensitizes Oral Squamous Cell Carcinoma by Inhibiting AKT/mTOR Axis and Inducing G1/G2/M Cell Cycle Arrest |
| Q34669344 | Activation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas |
| Q41936178 | Adeno-Associated Viral Vector-Mediated mTOR Inhibition by Short Hairpin RNA Suppresses Laser-Induced Choroidal Neovascularization |
| Q36879470 | Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers |
| Q38818652 | Anti-tumoral effect of arsenic compound, sodium metaarsenite (KML001), in non-Hodgkin's lymphoma: an in vitro and in vivo study. |
| Q38966925 | Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS-126 in models of ovarian cancer. |
| Q43461214 | Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect |
| Q50299737 | Association between PIK3CA alteration and prognosis of gastric cancer patients: a meta-analysis |
| Q58780065 | Biological Aspects of mTOR in Leukemia |
| Q34663710 | Biological characteristics and genetic heterogeneity between carcinoma-associated fibroblasts and their paired normal fibroblasts in human breast cancer |
| Q43378663 | Cat Mammary Tumors: Genetic Models for the Human Counterpart |
| Q90747767 | Chemopreventive Effects of Licorice and Its Components |
| Q54112059 | Combining the mammalian target of rapamycin inhibitor, rapamycin, with resveratrol has a synergistic effect in multiple myeloma. |
| Q39142678 | Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma. |
| Q36865078 | Competitive but Not Allosteric mTOR Kinase Inhibition Enhances Tumor Cell Radiosensitivity. |
| Q89162740 | Corilagin inhibits breast cancer growth via reactive oxygen species-dependent apoptosis and autophagy |
| Q27684223 | Crystal Structures of PI3Kα Complexed with PI103 and Its Derivatives: New Directions for Inhibitors Design |
| Q91765967 | Dieckol inhibits non-small-cell lung cancer cell proliferation and migration by regulating the PI3K/AKT signaling pathway |
| Q28080874 | Disruptive environmental chemicals and cellular mechanisms that confer resistance to cell death |
| Q42027870 | Dramatic antitumor effects of the dual mTORC1 and mTORC2 inhibitor AZD2014 in hepatocellular carcinoma |
| Q33727426 | EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas |
| Q39171575 | Effects of hypoxia-inducible factor-1α silencing on the proliferation of CBRH-7919 hepatoma cells |
| Q61801181 | Elevated expression of ciRS-7 in peripheral blood mononuclear cells from rheumatoid arthritis patients |
| Q36741115 | Euphorbia fischeriana Steud inhibits malignant melanoma via modulation of the phosphoinositide-3-kinase/Akt signaling pathway |
| Q39150764 | Everolimus as second-line therapy for metastatic renal cell carcinoma: a 'real-life' study. |
| Q38032923 | Everolimus for the treatment of pancreatic neuroendocrine tumors |
| Q49227179 | Gene and Protein Expression Profiles in a Mouse Model of Collagen-Induced Arthritis |
| Q90291133 | Genetic alterations in anaplastic thyroid carcinoma and targeted therapies |
| Q33891516 | HDAC class I inhibitor, Mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation |
| Q54979563 | Heat Stress and Hepatic Laser Thermal Ablation Induce Hepatocellular Carcinoma Growth: Role of PI3K/mTOR/AKT Signaling. |
| Q34718388 | Huaier aqueous extract inhibits ovarian cancer cell motility via the AKT/GSK3β/β-catenin pathway |
| Q42324668 | IDO1 involvement in mTOR pathway: a molecular mechanism of resistance to mTOR targeting in medulloblastoma |
| Q98159008 | IQGAP3 promotes cancer proliferation and metastasis in high-grade serous ovarian cancer |
| Q37629003 | Impacts of the mTOR gene polymorphisms rs2536 and rs2295080 on breast cancer risk in the Chinese population |
| Q36678103 | Inhibition of mTOR by apigenin in UVB-irradiated keratinocytes: A new implication of skin cancer prevention |
| Q36525180 | Inhibition of p85, the non-catalytic subunit of phosphatidylinositol 3-kinase, exerts potent antitumor activity in human breast cancer cells. |
| Q38068566 | Inside out: targeting NHE1 as an intracellular and extracellular regulator of cancer progression |
| Q36873574 | Insulin-like growth factor--phosphatidylinositol 3 kinase signaling in canine cortisol-secreting adrenocortical tumors |
| Q37375027 | Isoangustone A, a novel licorice compound, inhibits cell proliferation by targeting PI3K, MKK4, and MKK7 in human melanoma |
| Q34182679 | MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma |
| Q89261614 | MTOR pathway in focal cortical dysplasia type 2: What do we know? |
| Q37118693 | Modulating roles of amiloride in irradiation-induced antiproliferative effects in glioblastoma multiforme cells involving Akt phosphorylation and the alternative splicing of apoptotic genes |
| Q26774636 | Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies |
| Q36905878 | Mutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers |
| Q37641562 | Novel B55α-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest |
| Q54246295 | Overexpression of 3-phosphoinositide-dependent protein kinase-1 is associated with prognosis of gastric carcinoma. |
| Q37252398 | PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma |
| Q30300538 | PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia |
| Q54094662 | PIAS1 inhibited the metastasis of gastric cancer cell by epithelial-mesenchymal transition regulation within the inflammatory microenvironment. |
| Q37255490 | PRL-3 promotes the peritoneal metastasis of gastric cancer through the PI3K/Akt signaling pathway by regulating PTEN. |
| Q37132224 | Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells |
| Q33410761 | Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma |
| Q39004520 | Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells. |
| Q34571048 | Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies |
| Q44312541 | Predicting effects of kinase inhibitor in therapy for myeloid malignancies - the challenges in capturing disease heterogeneity |
| Q36070010 | Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review |
| Q27853211 | RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors |
| Q43181416 | Rapamycin, an mTOR inhibitor, induced apoptosis via independent mitochondrial and death receptor pathway in retinoblastoma Y79 cell |
| Q58766017 | Role of mTOR Signaling in Tumor Microenvironment: An Overview |
| Q48252277 | STAT3-induced lncRNA HAGLROS overexpression contributes to the malignant progression of gastric cancer cells via mTOR signal-mediated inhibition of autophagy |
| Q39141798 | Safety profile and treatment response of everolimus in different solid tumors: an observational study |
| Q64250706 | Significance of EGFR and PTEN Expression and PLR and NLR for Predicting the Prognosis of Epithelioid Malignant Peritoneal Mesothelioma |
| Q91612580 | Somatic mutational profiles of stage II and III gastric cancer according to tumor microenvironment immune type |
| Q36815271 | Stalling the engine of resistance: targeting cancer metabolism to overcome therapeutic resistance |
| Q38508406 | Subcellular functions of proteins under fluorescence single-cell microscopy |
| Q38187197 | Synergism between mTOR pathway and ultraviolet radiation in the pathogenesis of squamous cell carcinoma and its implication for solid-organ transplant recipients |
| Q28541805 | Synergistic effects of targeted PI3K signaling inhibition and chemotherapy in liposarcoma |
| Q41144441 | TRIM59 is a novel potential prognostic biomarker in patients with non-small cell lung cancer: A research based on bioinformatics analysis |
| Q36198145 | Tanshinone IIA combined with adriamycin inhibited malignant biological behaviors of NSCLC A549 cell line in a synergistic way. |
| Q38760024 | Targeting autophagy as a strategy for drug discovery and therapeutic modulation |
| Q34177843 | Targeting mTORC1-mediated metabolic addiction overcomes fludarabine resistance in malignant B cells. |
| Q38113583 | Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia |
| Q38262500 | Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment |
| Q38070195 | Targeting the PI3K/Akt/mTOR axis by apigenin for cancer prevention |
| Q38846141 | Temsirolimus targets multiple hallmarks of cancer to impede mesothelioma growth in vivo |
| Q40175289 | The Effects of Amiloride on Seizure Activity, Cognitive Deficits and Seizure-Induced Neurogenesis in a Novel Rat Model of Febrile Seizures |
| Q26778934 | The La-Related Proteins, a Family with Connections to Cancer |
| Q35680138 | The PI3K/Akt/PTEN/mTOR pathway: a fruitful target for inducing cell death in rheumatoid arthritis? |
| Q34309903 | The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma |
| Q38092648 | The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics |
| Q37577442 | The epigenetic modifier trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and epithelial-mesenchymal transition of lens epithelial cells |
| Q37409754 | The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells. |
| Q39122115 | The radiosensitizing effect of Paeonol on lung adenocarcinoma by augmentation of radiation-induced apoptosis and inhibition of the PI3K/Akt pathway |
| Q37408300 | The spatial structure of cell signaling systems |
| Q38208069 | Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations |
| Q41301287 | Toward system-level understanding of baculovirus-host cell interactions: from molecular fundamental studies to large-scale proteomics approaches |
| Q36656352 | VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer |
| Q35135634 | What Tumor Dynamics Modeling Can Teach us About Exploiting the Stem-Cell View for Better Cancer Treatment |
| Q36939981 | Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma |
| Q48530866 | mTOR Cross-Talk in Cancer and Potential for Combination Therapy. |
| Q90402737 | mTOR Inhibitor Therapy and Metabolic Consequences: Where Do We Stand? |
| Q89696584 | mTOR Regulation of Metabolism in Hematologic Malignancies |
| Q91923945 | mTOR Signaling Pathway in Cancer Targets Photodynamic Therapy In Vitro |
| Q64274877 | mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy |
| Q38737064 | mTOR inhibitors in urinary bladder cancer. |
| Q39208882 | mTOR pathway as a potential target in a subset of human medulloblastoma |
| Q36647928 | p110δ PI3 kinase pathway: emerging roles in cancer |
Search more.